Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05170802 · ClinicalTrials.gov registry record
Pancreatic Cancer & Surgical Resection
A clinical trial of Pancreas Cancer, sponsored by Methodist Health System.
- Recruiting
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT05170802: Recruiting study of Pancreas Cancer, sponsored by Methodist Health System.
NCT05170802 is a study of Pancreas Cancer that is actively recruiting participants, run by Methodist Health System. The registered enrollment target is 30 participants, below the 907-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05170802, a study of Pancreas Cancer, is actively recruiting participants, sponsored by Methodist Health System.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Primary Objective(s) To collect clinical data related to the treatment outcomes of Pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with pancreatic cancer requiring surgical intervention. Secondary Objective(s) To collect data on adverse events and complications related to IRE treatment. The AHPBA (Americas Hepato-Pancreato-Biliary Association) will be responsible for data collection and will periodically audit the data for quality assurance purposes. The AHPBA will review outcomes reported by each participating Research Institution and if outcomes are in the lower percentile, the investigators will be offered support to analyze the reasons for the suboptimal outcomes and may seek support to improve outcomes. The participating Research Institutions will receive a certificate annually that acknowledges their participation in the Research Project.
Conditions Studied
Interventions
- OTHER NanoKnife procedure
Study Locations (1)
Texas
- Liver Institute of Methodist Dallas Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-12-20 |
| Est. Completion | 2024-12 |
What NCT05170802 shows while recruiting
NCT05170802 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 907-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Pancreas Cancer appearing as the primary indexed condition, and to 1 intervention - of which NanoKnife procedure is the first listed.
NCT05170802 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05170802 about?
NCT05170802 is a clinical study titled "Pancreatic Cancer & Surgical Resection". Primary Objective(s) To collect clinical data related to the treatment outcomes of Pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with pancreatic cancer requiring surgical intervention. Secondary Objective(s) To collect data o...
What is the current status of trial NCT05170802?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2017-12-20. Estimated completion is 2024-12.
What conditions does trial NCT05170802 study?
This clinical trial studies the following conditions: Pancreas Cancer.
What interventions are being tested in trial NCT05170802?
The interventions under investigation include: NanoKnife procedure (OTHER).
Who is sponsoring clinical trial NCT05170802?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05170802 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreas Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05170802's enrollment target sits among peer trials
30 41st of 54 higher than 13 of 54 other Pancreas Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreas Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
RECRUITING
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
The Cancer of the Pancreas Screening-5 CAPS5)Study
RECRUITING · Phase 3
-
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI